# Advanced Biomed Inc.

**ADVB**

Nasdaq; healthcare; SIC 8071, Services-Medical Laboratories; CIK 0001941029

# None

### No letter

4 of 13 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $13.8M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution, late filer, thin data<br>not computable: short runway, distress, fortress balance sheet |
| **Inputs computable** | 4 of 13 |
| **Graded from** | filings received through Oct 13, 2026<br>36 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026 |
| **Last close** | $2.15<br>2026-11-17; market equity $3.6M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Oct 8, 2025*

in the State of Nevada. We operate through Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan is responsible for the main operation and the design and development of the company's primary technologies and products. Since our establishment in 2014, we have been focusing on the integration of multiple interdisciplinary technologies and established our own microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, we have developed various advanced and original research through the joint application of semiconductor technology and biotechnology.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 97.7** | | | | | | |
| Gross profitability | not computable | 32.8% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.6% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | 47.1% | (6.7%) | 97.7 | 756 | 2026-06-30 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 15.1** | | | | | |
| Altman Z double-prime | 8.58 | 0.31 | 11.5 | 705 | 2026-06-30 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (3.61x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 9.33x | 2.68x | 18.7 | 781 | 2026-06-30 |
| **Growth and financing, sleeve percentile 76.8** | | | | | |
| Revenue growth, three-year compound | not computable | 9.6% | | | |
| *four annual observations are required; found 1* | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.1% | | | |
| *four consecutive annual FCF observations are required; found 1* | | | | | |
| Reinvestment rate | not computable | 33.9% | | | |
| *required facts have no common fiscal period end* | | | | | |
| Asset growth, three years | not computable | 3.2% | | | |
| *four annual observations are required; found 2* | | | | | |
| Net share issuance, one year | 52.7% | 1.6% | 76.8 | 625 | 2026-10-13 |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 52.7% |
| Late filer | found 3 NT 10-K/Q filings in the last eight quarters |
| Thin data | 4 of 13 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-17 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (35.2%) | (1.7%) | 27 |
| Distance from 52-week high | (88.9%) | (30.5%) | 5 |
| EBIT to enterprise value | not computable | 0.5% | |
| Free cash flow yield | (168.8%) | 0.5% | 5 |
| Book value to price | 3.25 | 0.28 | 96 |
| Sales to price | 0.04 | 0.36 | 7 |
| Composite equity issuance, five years | not computable | 13.5% | |
| Relative strength against the sector, log excess return | (0.61) | (0.19) | 27 |
| Twelve-month failure probability, CHS model | not computable | 0.06% | |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2026-06-30** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | pass |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a |
| Months of runway | not finite |
| Days since last periodic filing | 6 (10-Q received Nov 12, 2026) |
| Median daily dollar volume, 63 sessions | $112,554 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | $6.7M | 2026-06-30 | 2026-10-13 | 10-K | 26-109029 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$1.9M | 2026-06-30 | 2026-10-13 | 10-K | 26-109029 |
| 3 | assets | us-gaap:Assets | $13.8M | 2026-06-30 | 2026-10-13 | 10-K | 26-109029 |
| 4 | assets | us-gaap:Assets | $22.9M | 2025-06-30 | 2026-10-13 | 10-K | 26-109029 |
| 5 | current assets | us-gaap:AssetsCurrent | $13.7M | 2026-06-30 | 2026-10-13 | 10-K | 26-109029 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $1.5M | 2026-06-30 | 2026-10-13 | 10-K | 26-109029 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$12.6M | 2026-06-30 | 2026-10-13 | 10-K | 26-109029 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$6.2M | 2026-06-30 | 2026-10-13 | 10-K | 26-109029 |
| 9 | book equity | us-gaap:StockholdersEquity | $12.3M | 2026-06-30 | 2026-10-13 | 10-K | 26-109029 |
| 10 | liabilities | us-gaap:Liabilities | $1.5M | 2026-06-30 | 2026-10-13 | 10-K | 26-109029 |
| 11 | revenue | us-gaap:Revenues | $127,637 | 2026-06-30 | 2026-10-13 | 10-K | 26-109029 |
| 12 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 1,652,133 | 2026-10-13 | 2026-10-13 | 10-K | 26-109029 |
| 13 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 21,640,000 | 2025-10-08 | 2025-10-08 | 10-K | 25-097465 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.